 "Image courtesy: Orbicular Pharmaceutical")
Alembic Pharmaceuticals Ltd (APL) has formed a 60:40 joint venture (JV) with the Hyderabad-based Orbicular Pharmaceutical Technologies Pvt Ltd to develop & commercialise dermatology products for global markets.
“Alembic Pharmaceuticals has entered into joint venture agreement with Orbicular Pharmaceutical Technologies Private Limited (Orbicular) and Dr M S Mohan to develop, manufacture and commercialise dermatology products for global markets,” said APL in a press release.
Orbicular has capabilities in developing dermatology products with a fully-equipped and staffed research laboratory in Hyderabad and has a pipeline of products under various stages of development. Manufacturing facility will be established in Aleor Dermaceuticals to enable worldwide registrations, it added.
Orbicular business model revolves around building a product portfolio of niche generic and specialty pharmaceutical products and its licensure at mid or late stage. Orbicular focuses on broad range of innovative, differentiated and complex products mainly in niche dosage domains like injectables, ophthalmics, otics, oral dosages and topical products.
